Table 1 Summary of logistic regression results for rs11098403 across cohorts.

Sample	Ethnicity	Case diagnosis	Total samples	Controls	Cases	MAF controls	MAF cases	Odds ratio	Additive P -value	Reference (see supplement)
Discovery
Ashkenazi*	Caucasian	Schizophrenia	2,544	1,640	904	0.38	0.47	1.41	6.55E−09
Replication/extension
MGS EA	Caucasian	Schizophrenia	4,942	2,056	2,886	0.27	0.28	1.05	0.127	49
ZHH	Caucasian	Schizophrenia	317	140	177	0.29	0.32	1.15	0.208	50
MGS AA*	African–American	Schizophrenia	1,875	954	921	0.25	0.27	1.09	0.12	49
Japan*	Asian	Schizophrenia	1,080	530	550	0.16	0.17	1.06	0.238	51
Munich	Caucasian	Schizophrenia	842	412	430	NA	NA	1.1	0.287	52
Aberdeen	Caucasian	Schizophrenia	892	441	451	NA	NA	1.21	0.03	52
GAIN	Caucasian	Bipolar	1,710	689	1,021	0.25	0.28	1.13	0.058	53
German	Caucasian	Bipolar	1,982	1,300	682	0.29	0.31	1.05	0.255	54
WTCCC	Caucasian	Bipolar	4,806	2,938	1,868	0.25	0.27	1.1	0.019	55
Taiwan*	Asian	Bipolar	2,000	1,000	1,000	0.15	0.16	1.06	0.25	56
Ashkenazi*	Caucasian	Bipolar	2,745	2,531	214	0.38	0.43	1.24	0.0177
All cohorts excluding discovery			23,191	12,991	10,200			1.09	1.46E−07
All cohorts			25,735	14,631	11,104			1.13	9.49E−12

AA, African–American; EA, European–American; GAIN, The Genetic-Association Information Network; MAF, minor allele frequency; MGS, molecular genetics of schizophrenia; WTCCC, The Wellcome Trust Case–Control Consortium; ZHH, The Zucker Hillside Hospital.
P-values are two-sided for the discovery cohort and combined analyses; one-sided P-values are listed for the replication cohorts.
Cohort details are available in Supplementary Note 1.
^*Cohorts not part of Psychiatric Genomics Consortium Phase 1 publications^7,10,11.

Quick links

Search